Among pandemic-era stocks, Moderna ($Moderna, Inc.(MRNA)$ ) may undoubtedly be one of the most extraordinary. Since 2020, the Cambridge, Massachusetts-based COVID-19 vaccine producer gained 680%, an impressive rally for its shares which vastly outperformed the competition. However, since the start of 2022, the biotech company's stock has tumbled more than 42% amid the broad market selloff in growth equities and signs that governments might be moving to end pandemic restrictions. Moderna closed Tuesday at $144.97. Moderna Weekly Chart Earlier, Britain announced it planned to end pandemic restrictions, becoming the first major Western government to do so. People with COVID-19 will no longer have to self-isolate from Thursday, while access to free tests